IMPACT BIOMEDICAL INC.

For the period ended Dec 31, 2024. Filed Mar 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 28, 2025

IBO$4.33+5.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	2024	2023
Costs and expenses:
Sales, general and administrative compensation (inclusive of stock based compensation)	$718,000	$315,000
Sales and marketing	633,000	65,000
Professional Fees	446,000	724,000
Research and development	278,000	1,685,000
Depreciation and Amortization	1,119,000	1,120,000
Rent and utilities	32,000	-
Impairment of fixed assets	263,000	-
Impairment of goodwill	25,093,000	-
Other operating expenses	171,000	119,000
Total costs and expenses	28,753,000	4,028,000
Operating loss	(28,753,000)	(4,028,000)
Other income (expense):
Interest income	13,000	13,000
Other income	-	52,000
Change in fair value of note payable, related party	5,068,000	-
Interest expense	(1,065,000)	(444,000)
Loss from operations before income taxes	(24,737,000)	(4,407,000)
Income tax expense	(33,000)	-
Net loss	$(24,770,000)	$(4,407,000)
Loss from operations attributed to noncontrolling interest	62,000	71,000
Net income (loss) attributable to common stockholders	$(24,708,000)	$(4,336,000)
Earnings (loss) per common share:
Basic	$(2.30)	$(0.07)
Diluted	$(2.30)	$(0.07)
Shares used earnings (loss) per common share:
Basic	10,757,147	60,248,078
Diluted	10,757,147	60,248,078

**I

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.